Low-dose 5-Aza-2′-deoxycytidine pretreatment inhibits experimental autoimmune encephalomyelitis by induction of regulatory T cells

Molecular Medicine

Volumn 20, Issue 1, 2014, Pages 248-256

  Chan, Michael W Y ^a   Chang, Chia Bin ^a   Tung, Chien Hsueh ^a,b   Sun, Justin ^a   Suen, Jau Ling ^c   Wu, Shu Fen ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^b Buddist Tzu Chi College of Nursing   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GAMMA INTERFERON; INTERLEUKIN 17; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TRANSCRIPTION FACTOR FOXP3; AZACITIDINE; DECITABINE; DNA METHYLTRANSFERASE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; MOG PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ GFP- T LYMPHOCYTE CELL; CELL FUNCTION; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FOXP3 GENE; IN VITRO STUDY; LOW DRUG DOSE; MOUSE; NERVE CELL INHIBITION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; SPINAL CORD; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; AZACITIDINE; DNA MODIFICATION METHYLASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; MICE, INBRED C57BL; MICE, TRANSGENIC; MYCOBACTERIUM TUBERCULOSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; SPINAL CORD; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84903381905     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2013.00159     Document Type: Article

References (41)

1. Goverman JM. (2011) Immune tolerance in multiple sclerosis. Immunol. Rev. 241:228-40.
2. Pachner AR. (2011) Experimental models of multiple sclerosis. Curr. Opin. Neurol. 24:291-99.
3. Simmons SB, Pierson ER, Lee SY, Goverman JM. (2013) Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol. 34:410-22.
4. Rangachari M, Kuchroo VK. (2013) Using EAE to better understand principles of immune function and autoimmune pathology. J. Autoimmun. 45:31-9.
5. Kroenke MA, Segal BM. (2007) Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 85:1685-93.
6. Petermann F, Korn T. (2011) Cytokines and effector T cell subsets causing autoimmune CNS disease. FEBS Lett. 585:3747-57.
7. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. (2010) T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162:1-11.
8. Sakaguchi S. (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6:345-52.
9. Goldstein JD, et al. (2013) Role of cytokines in thymus-versus peripherally derived-regulatory T cell differentiation and function. Front Immunol. 4:155.
10. Zhou X, et al. (2011) Therapeutic potential of TGFbeta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity. 44:43-50.
11. Shevach EM. (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 30:636-45.
12. Vignali DA, Collison LW, Workman CJ. (2008) How regulatory T cells work. Nat. Rev. Immunol. 8:523-32.
13. Matsushita T, Horikawa M, Iwata Y, Tedder TF. (2010) Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J. Immunol. 185:2240-52.
14. Williams LM, Rudensky AY. (2007) Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8:277-84.
15. Apostolou I, et al. (2008) Peripherally induced Treg: mode, stability, and role in specific tolerance. J. Clin. Immunol. 28:619-24.
16. Curotto de Lafaille MA, Lafaille JJ. (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 30:626-35.
17. Bennett CL, et al. (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27:20-1.
18. Lal G, Bromberg JS. (2009) Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 114:3727-35.
19. Katoh H, Zheng P, Liu Y. (2013) FOXP3: genetic and epigenetic implications for autoimmunity. J. Autoimmun. 41:72-8.
20. Foulks JM, et al. (2012) Epigenetic drug discovery: targeting DNA methyltransferases. J. Biomol. Screen. 17:2-17.
21. Floess S, et al. (2007) Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5:e38.
22. Polansky JK, et al. (2008) DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38:1654-63.
23. Zheng Q, et al. (2009) Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice. J. Mol. Med. (Berl). 87:1191-205.
24. Sanchez-Abarca LI, et al. (2010) Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 115:107-21.
25. Lal G, et al. (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182:259-73.
26. Frikeche J, et al. (2011) Impact of the hypomethylating agent 5-azacytidine on dendritic cells function. Exp. Hematol. 39:1056-63.
27. Racke MK. (2001) Experimental autoimmune encephalomyelitis (EAE). Curr. Protoc. Neurosci. Chapter 9:Unit 9.7.
28. Bilate AM, Lafaille JJ. (2012) Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu. Rev. Immunol. 30:733-58.
29. Janson PC, et al. (2008) FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One. 3:e1612.
30. Choi J, et al. (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 116:129-39.
31. Zheng Y, et al. (2010) Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature. 463:808-12.
32. Chauhan SK, Saban DR, Lee HK, Dana R. (2009) Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J. Immunol. 182:148-53.
33. Moon C, et al. (2009) Use of epigenetic modification to induce FOXP3 expression in naive T cells. Transplant. Proc. 41:1848-54.
34. Wong CP, et al. (2011) Induction of regulatory T cells by green tea polyphenol EGCG. Immunol. Lett. 139:7-13.
35. Hu Y, et al. (2013) Decitabine facilitates the generation and immunosuppressive function of regulatory gammadelta T cells derived from human peripheral blood mononuclear cells. Leukemia. 27:1580-5.
36. Janson PC, et al. (2011) Profiling of CD4+ T cells with epigenetic immune lineage analysis. J. Immunol. 186:92-102.
37. Haak S, et al. (2009) IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 119:61-9.
38. Segal BM. (2010) Th17 cells in autoimmune demyelinating disease. Semin. Immunopathol. 32:71-7.
39. Liggett T, et al. (2010) Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 290:16-21.
40. Sojka DK, Huang YH, Fowell DJ. (2008) Mechanisms of regulatory T-cell suppression: a diverse arsenal for a moving target. Immunology. 124:13-22.
41. Kehrmann J, et al. (2014) Impact of 5-aza-2(-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells. Immunology. 142:384-95.